Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway

Author(s): Yijun Huang*, Hong Zhang

Journal Name: Current Cancer Therapy Reviews

Volume 13 , Issue 2 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: T cell activation via the blockade of PD-1 pathway has been recognized as an emerging drug target for cancer immunotherapy which provides a rationale for clinical trials in cancer patients. The recent breakthrough approvals of T cell checkpoint inhibitors targeting PD-1 pathway boost the era of immuno-oncology drugs.

Methods: The progress of PD-1 checkpoint inhibitor as a single agent in the field of immuno-oncology is reviewed. Antibodies targting PD-1 and PD-L1 with regulatroy approvals are discussed with the current coverage of indications. Other candidates in clinical investigations are also summarized.

Results: Monoclonal antibodies that block protein-protein interactions between PD-1 and its ligand have shown the promise for the treatment of a variety of cancer types. The fast growing family of PD-1 checkpoint inhibitors been observed both in regulatroy approvals and clinical investigations.

Conclusion: The potential use of PD-1 checkpoint inhibitor alone or in combination with other agents is substantial, and will further reveal the important role of PD-1 pathway in immunomodulation and disease control.

Keywords: PD-1, PD-L1, checkpoint inhibitors, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 15 November, 2017
Page: [120 - 128]
Pages: 9
DOI: 10.2174/1573394713666170824125158
Price: $65

Article Metrics

PDF: 28
PRC: 1